Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor

Trial Profile

Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Plerixafor (Primary)
  • Indications Cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 11 Jul 2018 Status changed from suspended to discontinued.
    • 14 Dec 2017 Planned End Date changed from 31 Aug 2018 to 31 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top